Telix Pharmaceuticals Limited (NASDAQ:TLX) Stock Has Average Target Price of $20.50

Shares of Telix Pharmaceuticals Limited (NASDAQ:TLX) have been assigned a consensus recommendation of “Buy” from the six ratings firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation, four have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $20.50.

Several equities research analysts have recently weighed in on TLX shares. HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of Telix Pharmaceuticals in a report on Friday, September 25th. Wedbush reaffirmed an “outperform” rating and issued a $22.00 target price on shares of Telix Pharmaceuticals in a report on Wednesday, September 23rd. Royal Bank Of Canada upgraded Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research report on Monday, September 21st. Weiss Ratings upgraded Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a research note on Friday, August 21st. Finally, Citigroup reissued a “buy” rating on shares of Telix Pharmaceuticals in a report on Thursday, August 20th.

Hedge Funds Weigh In On Telix Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. XY Capital Ltd increased its holdings in Telix Pharmaceuticals by 468.0% in the second quarter. XY Capital Ltd now owns 71,291 shares of the company’s stock valued at $822,000 after buying an additional 58,739 shares in the last quarter. Hennion & Walsh Asset Management Inc. purchased a new stake in shares of Telix Pharmaceuticals during the 2nd quarter worth approximately $1,731,000. Bank of America Corp DE boosted its stake in shares of Telix Pharmaceuticals by 523.8% during the 1st quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock worth $96,000 after acquiring an additional 8,423 shares in the last quarter. Lazard Asset Management LLC grew its holdings in shares of Telix Pharmaceuticals by 15.7% in the 1st quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock worth $2,775,000 after acquiring an additional 39,400 shares during the period. Finally, Private Advisor Group LLC grew its holdings in shares of Telix Pharmaceuticals by 276.3% in the 1st quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock worth $1,669,000 after acquiring an additional 128,070 shares during the period.

Telix Pharmaceuticals Price Performance

Shares of Telix Pharmaceuticals stock opened at $10.97 on Monday. The company has a current ratio of 2.01, a quick ratio of 1.85 and a debt-to-equity ratio of 1.16. Telix Pharmaceuticals has a 52 week low of $6.28 and a 52 week high of $13.11. The firm’s 50 day moving average is $11.39 and its two-hundred day moving average is $10.57.

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals and molecularly targeted radiation products. Its technologies are designed to help identify disease through medical imaging and, in some cases, deliver radiation directly to targeted cancer cells.

The company’s primary commercial product is Illuccix (kit for the preparation of gallium-68 gozetotide injection), a positron emission tomography imaging agent used to identify prostate-specific membrane antigen-positive lesions in adults with prostate cancer.